Comparison · NCT05823012-d16ebe60
All Participants vs Participants Who Entered Maintenance Period: Proportion of Participants With Normalized TSH at End of Maintenance Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. All Participants vs Participants Who Entered Maintenance Period: Proportion of Participants With Normalized TSH at End of Maintenance Period. Trial comparisons, record NCT05823012-d16ebe60. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05823012-d16ebe60
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.674 | 0.53 | 0.791 | wilson | |
| Risk in group 2 | 0.738 | 0.589 | 0.847 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0642 | -0.245 | 0.125 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.913 | 0.697 | 1.2 | log | |
| Odds ratio, group 1 over group 2 | 0.733 | 0.291 | 1.85 | log | |
| Number needed to treat, for one fewer participant with the outcome on All Participants than on Participants Who Entered Maintenance Period | 15.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | All Participants | All participants who received at least 1 dose of XP-8121 (100 to 1500 μg subcutaneous injection). | 31 | 46 | OG000 |
| Group 2 | Participants Who Entered Maintenance Period | All participants who received XP-8121 (100 to 1500 μg subcutaneous injection), completed the Titration Period, and entered the Maintenance Period. | 31 | 42 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Participants With Normalized TSH at End of Maintenance Period
- Description
- Proportion of participants enrolled with normalized TSH at the end of the Maintenance Period.
- Time frame
- Day 29 of the Maintenance Period
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
- NCT number
- NCT05823012
- Phases
- PHASE2
- Conditions
- Hypothyroidism
- Interventions
- levothyroxine sodium
- Lead sponsor
- Xeris Pharmaceuticals
- Results first posted
- 2025-07-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05823012?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05823012-d16ebe60